Progress in the study of antiviral activity of cepharanthine against SARS-CoV-2.

Author: Hua Hao FAN ¹ ; Ke LIU ¹ ; Bi Xia HONG ¹ ; Shi Ting HE ¹ ; Peng Jun HAN ¹ ; Mao Chen LI ¹ ; Shu Qi WANG ¹ ; Yi Gang TONG ¹
Author Information

1. College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Publication Type:Journal Article
Keywords: SARS-CoV-2; cepharanthine; research progress
MeSH: Antiviral Agents/therapeutic use*; Benzylisoquinolines/therapeutic use*; COVID-19; Humans; SARS-CoV-2
From: Journal of Southern Medical University 2022;42(6):955-956
CountryChina
Language:Chinese
Abstract: As a member of the dibenzyl isoquinoline alkaloid family, cepharathine is an alkaloid from the traditional Chinese medicine cepharathine, which is mainly used for treatment of leukopenia and other diseases. Recent studies of the inhibitory effect of cepharathine against SARS-CoV-2 have attracted widespread attention and aroused heated discussion. As the original discoverer of the anti-SARS-CoV-2 activity of cepharanthine, here we briefly summarize the discovery of cepharanthine and review important progress in relevant studies concerning the discovery and validation of anti-SARS-CoV-2 activity of cepharathine, its antiviral mechanisms and clinical trials of its applications in COVID-19 therapy.